Anteris Technologies Ltd. (AVR)
NASDAQ
Closed
Aug 24, 2026
Day's Range
8.6652 wk Range
3.30Overview - AVR - Anteris Technologies Ltd.
Key Statistics
Valuation
Enterprise Value
621.91M
P/E (Trailing)
‪-3.51‬
P/E (Forward)
‪-9.30‬
PEG Ratio
‪0.06‬
Price / Sales (TTM)
‪390.35‬
Price / Book
‪3.47‬
EV / EBITDA
‪-5.95‬
Profitability
Gross Margin
‪76.92%‬
Profit Margin
‪70.25%‬
Operating Margin
‪-3,072.05%‬
Return on Assets
‪-42.50%‬
Return on Equity
‪-74.65%‬
Ownership
Shares Outstanding
97.23M
Float
65.79M
Short % of Shares Outstanding
‪10.48%‬
Held by Insiders
‪16.46%‬
Held by Institutions
‪70.81%‬
Price stats
50-Day Avg
‪9.11‬
200-Day Avg
‪6.64‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
3 analysts
Average price target
‪$ 15.33‬Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - AVR - Anteris Technologies Ltd.
Peers - AVR - Anteris Technologies Ltd.
Peer Comparison
Compared with companies in Medical Instruments & Supplies listed on NASDAQ.
Profile Summary - AVR - Anteris Technologies Ltd.
About
Anteris Technologies Ltd. is a structural heart company that designs, develops, and commercializes innovative medical devices for treating heart valve diseases. Its flagship product, the DurAVR Transcatheter Heart Valve system, features a single-piece, native-shaped biomimetic design engineered to mimic the…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
